Primary Immunodeficiency Diseases (PID) — Immune Globulin Subcutaenous (Human), 20%
Citation(s)
A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases